CE marking opens the European market. Reimbursement determines whether your device gets used. France, Germany, the UK, and Italy each operate independent national reimbursement systems with distinct timelines, bodies, and clinical evidence requirements. This guide covers each country — with the practical detail C-suite decisions require.
Four major European markets, four distinct national systems. No European-level reimbursement body exists — each Member State assesses independently. CE marking is a prerequisite for all, but confers no reimbursement rights in any.
| Country | Reimbursement body | Key pathway | Primary evidence requirement | Typical timeline (CE to reimbursement) |
|---|---|---|---|---|
| 🇫🇷France | HAS (Haute Autorité de Santé) CEPS for price negotiation |
LPPR listing (Liste des Produits et Prestations Remboursables) | SSMR (service rendu) + ASMR (amélioration du service rendu). RCT or comparative study preferred. | 18–36 months |
| 🇩🇪Germany | GKV-SV (statutory health insurers) BfArM for DiGA pathway |
DRG / NUB (new diagnostic and therapeutic methods) or DiGA for SaMD | Clinical benefit vs. standard of care. RWE accepted for NUB. DiGA: pilot study within 12 months. | 12–24 months (NUB) 3 months (DiGA fast-track) |
| 🇬🇧UK (post-Brexit) | NICE (National Institute for Health and Care Excellence) NHS England |
NICE MedTech Assessment (MTA) or Early Value Assessment (EVA) | Clinical and cost-effectiveness evidence. QALY framework. Real-world evidence increasingly accepted. | 18–36 months (full MTA) 6–12 months (EVA pathway) |
| 🇮🇹Italy | AIFA (Agenzia Italiana del Farmaco) Ministry of Health for devices |
National tariff listing (DRG/DM tariffs) or regional procurement | Clinical evidence of safety and performance. Strong reliance on clinical registries (national and regional). | 24–48 months (national) |
Each system is detailed below with the specific steps, evidence requirements, and practical timelines that commercial and regulatory teams need to plan market access strategy.
France's reimbursement system for medical devices is among the most demanding in Europe. The HAS (Haute Autorité de Santé) evaluates each device on two criteria: the SSMR (service rendu — clinical benefit) and ASMR (amélioration du service rendu — improvement in clinical benefit versus existing alternatives). A high SSMR is necessary for reimbursement; a high ASMR drives a higher reimbursed price in the CEPS negotiation.
Following HAS opinion, CEPS (Comité Économique des Produits de Santé) negotiates the reimbursed price with the manufacturer. This is a separate and often lengthy process that can extend the total pathway to 36 months or more for novel devices.
The French reimbursement dossier requires clinical evidence demonstrating clinical benefit (SSMR) and ideally improvement over existing alternatives (ASMR). CNEDiMTS gives highest weight to comparative randomised controlled trial data, but will accept observational study data or retrospective analysis for devices where RCTs are not feasible.
Germany offers two distinct reimbursement pathways depending on device type. The NUB (Neue Untersuchungs- und Behandlungsmethoden) pathway covers traditional medical devices via hospital DRG funding or outpatient reimbursement through the GKV-SV (statutory health insurance system). For digital health applications classified as SaMD, the DiGA pathway offers one of the fastest reimbursement routes in Europe.
Germany's hospital system is significant: devices used in hospital settings are typically funded through DRG codes or NUB applications submitted by individual hospitals to the InEK (Institute for Hospital Reimbursement). An approved NUB grants one year of temporary reimbursement while a permanent DRG code is negotiated.
The DiGA pathway under Germany's Digital Supply Act (Digitale-Versorgung-Gesetz, DVG) is the fastest reimbursement route for SaMD in Europe. A CE-marked digital health application can be listed in the BfArM DiGA directory within 3 months — at which point it can be prescribed by any statutory health insurance (GKV) physician and reimbursed at the manufacturer's listed price.
Following Brexit, the UK operates an entirely independent regulatory and reimbursement pathway. UKCA marking (or CE marking under the existing recognition period) is required for market access. Reimbursement decisions are made nationally by NICE and commissioned by NHS England — with devolved purchasing decisions in Scotland (SMC/SGHD), Wales (AWMSG), and Northern Ireland (PHA).
NICE conducts MedTech Assessments (MTA) for devices of significant innovation or cost impact. For devices entering earlier in the evidence cycle, the Early Value Assessment (EVA) pathway provides provisional NHS access while post-market evidence is generated — a model designed to avoid the NICE "innovation trap" where devices cannot get evidence without NHS use.
NICE evaluates medical devices using an incremental cost-effectiveness framework, expressing outcomes in Quality-Adjusted Life Years (QALYs). A cost per QALY below £20,000–30,000 is typically acceptable. For devices where QALY measurement is not straightforward, NICE accepts alternative outcome measures provided they are clearly linked to clinically meaningful endpoints.
Italy's medical device reimbursement landscape is notably fragmented. At the national level, the Ministry of Health maintains the national nomenclature (Repertorio dei dispositivi medici) and DRG-based hospital tariffs. However, reimbursement decisions for many devices — particularly high-cost Class III implants — are made at the regional level (Regioni), leading to significant access disparities across the country.
AIFA (Agenzia Italiana del Farmaco) is technically the pharmaceutical agency and has a primary role for drugs — for medical devices, the Ministry of Health's Direzione Generale dei Dispositivi Medici takes the lead. The national timeline for new device listing is among the longest in Europe, making regional market entry strategies important for manufacturers who cannot wait for national listing.
Italian reimbursement bodies place significant weight on clinical registry data — particularly national Italian registries and, for orthopaedic devices, registry data from NJR (UK) and EPRD (Germany) as European comparators. Manufacturer-sponsored RCTs are positively regarded but must include Italian sites to be considered representative of the Italian patient population.
Despite the national differences, every European reimbursement process is built on the same four constituents. Understanding each before starting the application is critical for manufacturers entering markets for the first time.
The full reimbursement pathway in France typically takes 18 to 36 months from CE marking to national LPPR listing. The process involves HAS CNEDiMTS evaluation (6–12 months), followed by price negotiation with CEPS (a further 6–24 months for innovative devices). For devices with existing LPP codes, temporary coverage under existing mechanisms may provide faster patient access. The ETAPES programme can accelerate access for certain digital or remote monitoring technologies.
DiGA (Digitale Gesundheitsanwendungen) is Germany's fast-track reimbursement pathway for digital health applications under the Digital Supply Act (DVG). A CE-marked SaMD can be listed in the BfArM DiGA directory within 3 months, at which point it can be prescribed by any GKV physician and reimbursed at the manufacturer's listed price. DiGA applies exclusively to software medical devices — hardware devices and implants follow the NUB or DRG pathway, which takes 12 to 24 months.
Yes, indirectly. EU MDR 2017/745 significantly raises the clinical evidence bar for CE marking — and the clinical evidence generated for EU MDR compliance is the same evidence that reimbursement bodies (HAS, GKV-SV, NICE, AIFA) evaluate when assessing clinical benefit. A stronger CER and PMCF programme directly strengthens the reimbursement dossier. Manufacturers who integrate reimbursement planning with their EU MDR clinical strategy save 12 to 18 months of commercial timeline and avoid generating duplicate evidence.
CE marking (via EU MDR 2017/745 and a Notified Body) certifies that a device meets safety and performance requirements — it is a legal prerequisite for market access across EU Member States. Reimbursement is a separate national-level process determining whether public health insurance systems will pay for the device. CE marking is required before any reimbursement application can proceed, but confers no reimbursement rights. Each EU Member State, plus the UK, has its own independent reimbursement system with distinct bodies, timelines, and evidence standards.
CE marking, PMCF, and clinical evidence — the foundations of a successful European reimbursement dossier.
Eclevar MedTech's market access team — led by Prof. Mark DaCosta — integrates reimbursement planning with EU MDR clinical evidence strategy from Day 1. Avoid generating duplicate clinical evidence for CE marking and reimbursement by designing a single evidence program that satisfies both.
